pubmed-article:20336787 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20336787 | lifeskim:mentions | umls-concept:C0281361 | lld:lifeskim |
pubmed-article:20336787 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
pubmed-article:20336787 | lifeskim:mentions | umls-concept:C0728940 | lld:lifeskim |
pubmed-article:20336787 | lifeskim:mentions | umls-concept:C0677850 | lld:lifeskim |
pubmed-article:20336787 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
pubmed-article:20336787 | pubmed:issue | 12 | lld:pubmed |
pubmed-article:20336787 | pubmed:dateCreated | 2010-6-21 | lld:pubmed |
pubmed-article:20336787 | pubmed:abstractText | The use of adjuvant chemoradiation for pancreatic adenocarcinoma (PAC) is accepted in North America, but there is a paucity of data to support this practice. The relation between adjuvant therapy and survival was assessed in a population-based cohort of patients with PAC. | lld:pubmed |
pubmed-article:20336787 | pubmed:language | eng | lld:pubmed |
pubmed-article:20336787 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20336787 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:20336787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20336787 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20336787 | pubmed:month | Jun | lld:pubmed |
pubmed-article:20336787 | pubmed:issn | 0008-543X | lld:pubmed |
pubmed-article:20336787 | pubmed:author | pubmed-author:BillingsleyKe... | lld:pubmed |
pubmed-article:20336787 | pubmed:author | pubmed-author:MoriMotomiM | lld:pubmed |
pubmed-article:20336787 | pubmed:author | pubmed-author:AustinDonald... | lld:pubmed |
pubmed-article:20336787 | pubmed:author | pubmed-author:SheppardBrett... | lld:pubmed |
pubmed-article:20336787 | pubmed:author | pubmed-author:MayoSkye CSC | lld:pubmed |
pubmed-article:20336787 | pubmed:author | pubmed-author:ShipleyDonald... | lld:pubmed |
pubmed-article:20336787 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:20336787 | pubmed:day | 15 | lld:pubmed |
pubmed-article:20336787 | pubmed:volume | 116 | lld:pubmed |
pubmed-article:20336787 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20336787 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20336787 | pubmed:pagination | 2932-40 | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:meshHeading | pubmed-meshheading:20336787... | lld:pubmed |
pubmed-article:20336787 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20336787 | pubmed:articleTitle | Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. | lld:pubmed |
pubmed-article:20336787 | pubmed:affiliation | Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA. | lld:pubmed |
pubmed-article:20336787 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:20336787 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |